Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Median time to recovery 26% Improvement Relative Risk Kirenga et al. HCQ for COVID-19 EARLY TREATMENT Is early treatment with HCQ beneficial for COVID-19? Prospective study of 56 patients in Uganda Faster recovery with HCQ (not stat. sig., p=0.2) Kirenga et al., BMJ Open Respiratory Research, doi:10.1136/bmjresp-2020-000646 Favors HCQ Favors control
Characteristics and outcomes of admitted patients infected with SARS-CoV-2 in Uganda
Kirenga et al., BMJ Open Respiratory Research, doi:10.1136/bmjresp-2020-000646
Kirenga et al., Characteristics and outcomes of admitted patients infected with SARS-CoV-2 in Uganda, BMJ Open Respiratory Research, doi:10.1136/bmjresp-2020-000646
Sep 2020   Source   PDF  
  All Studies   Meta
Prospective 56 patients in Uganda, 29 HCQ and 27 control, showing 25.6% faster recovery with HCQ, 6.4 vs. 8.6 days (p = 0.20). There was no ICU admission, mechanical ventilation, or death.
Treatment delay is not specified but at least a portion of patients appear to have been treated early.
median time to recovery, 25.6% lower, relative time 0.74, p = 0.20, treatment 29, control 27.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Kirenga et al., 9 Sep 2020, prospective, Uganda, peer-reviewed, 29 authors, dosage not specified.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: Characteristics and outcomes of admitted patients infected with SARS-­ CoV-2 in Uganda Bruce Kirenga ‍ ‍,1 Winters Muttamba,1 Alex Kayongo,1 Christopher Nsereko,2 Trishul Siddharthan,3 John Lusiba,4 Levicatus Mugenyi,1 Rosemary K Byanyima,5 William Worodria,6 Fred Nakwagala,7 Rebecca Nantanda,1 Ivan Kimuli,1 Winceslaus Katagira,1 Bernard Sentalo Bagaya,8 Emmanuel Nasinghe,8 Hellen Aanyu-­Tukamuhebwa,9 Beatrice Amuge,10 Rogers Sekibira,1 Esther Buregyeya,11 Noah Kiwanuka,11 Moses Muwanga,12 Samuel Kalungi,13 Moses Lutaakome Joloba,8 David Patrick Kateete,8 Baterana Byarugaba,7 Moses R Kamya,14 Henry Mwebesa,15 William Bazeyo16 To cite: Kirenga B, Muttamba W, Kayongo A, et al. Characteristics and outcomes of admitted patients infected with SARS-­CoV-2 in Uganda. BMJ Open Resp Res 2020;7:e000646. doi:10.1136/ bmjresp-2020-000646 ABSTRACT Rationale Detailed data on the characteristics and outcomes of patients with COVID-19 in sub-­Saharan Africa are limited. Objective We determined the clinical characteristics and treatment outcomes of patients diagnosed with COVID-19 in Uganda. Measurements As of the 16 May 2020, a total of 203 ►► Additional material is cases had been confirmed. We report on the first 56 published online only. To patients; 29 received hydroxychloroquine (HCQ) and 27 view, please visit the journal did not. Endpoints included admission to intensive care, online (http://​dx.​doi.​org/​10.​ mechanical ventilation or death during hospitalisation. 1136/​bmjresp-​2020-​000646). Main results The median age was 34.2 years; 67.9% were male; and 14.6% were <18 years. Up 57.1% of Received 21 May 2020 the patients were asymptomatic. The most common Revised 24 August 2020 symptoms were fever (21.4%), cough (19.6%), rhinorrhea Accepted 25 August 2020 (16.1%), headache (12.5%), muscle ache (7.1%) and fatigue (7.1%). Rates of comorbidities were 10.7% (pre-­existing hypertension), 10.7% (diabetes) and 7.1% (HIV), Body Mass Index (BMI) of ≥30 36.6%. 37.0% had a blood pressure (BP) of >130/90 mm Hg, and 27.8% had BP of >140/90 mm Hg. Laboratory derangements were leucopenia (10.6%), lymphopenia (11.1%) and thrombocytopenia (26.3%). Abnormal chest X-­ray was observed in 14.3%. No patients reached the primary endpoint. Time to clinical recovery was shorter among patients who received HCQ, but this difference did not reach statistical significance. Conclusion Most of the patients with COVID-19 presented with mild disease and exhibited a clinical trajectory not similar to other countries. Outcomes did not differ by HCQ treatment status in line with other concluded studies on © Author(s) (or their the benefit of using HCQ in the treatment of COVID-19. employer(s)) 2020. Re-­use permitted under CC BY-­NC. No commercial re-­use. See rights and permissions. Published by BMJ. For numbered affiliations see end of article. Correspondence to Dr Bruce Kirenga; ​brucekirenga@​yahoo.​co.​uk
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop